비교리스트

 카트 문의
시장보고서
상품코드
1375928

바이오마커 임상 단계 아웃소싱 서비스 시장 규모, 점유율, 동향 분석 보고서 : 바이오마커 유형별, 치료 분야별, 최종 용도별, 지역별, 부문별 예측(2023-2030년)

Biomarker Clinical Phase Outsourcing Services Market Size, Share & Trends Analysis Report By Biomarker Type (Predictive Biomarkers, Surrogate Endpoints), By Therapeutic Area, By End-use, By Region, And Segment Forecasts, 2023 - 2030
발행일: | 리서치사: Grand View Research | 페이지 정보: 영문 195 Pages | 배송안내 : 2-10일 (영업일 기준)

    
    
    




※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.

바이오마커 임상 단계 아웃소싱 서비스 시장 성장과 동향:

Grand View Research, Inc.의 최신 보고서에 따르면, 바이오마커 임상 단계 아웃소싱 서비스 세계 시장 규모는 2030년까지 271억 7,000만 달러에 달하고 CAGR 20.6%를 기록할 것으로 예상됩니다.

바이오마커의 진단적 활용 증가, OMICS 기술의 급속한 발전, 정부의 연구개발(R&D) 자금 증가, 정밀의료로의 전환은 시장 성장을 촉진하는 요인 중 일부입니다.

시장은 세분화되어 있으며, 여러 주요 기업들이 비슷한 기술력과 처리 능력을 보유하고 있습니다. 이들 기업은 분석법 개발, 샘플 분석, 데이터 해석, 임상시험 지원 등 다양한 바이오마커 검사 관련 서비스를 제공합니다. 이 산업은 품질 보증, 기술 발전, 규제 대응, 고부가가치 및 다양한 서비스 제공 능력 등의 요인으로 인해 경쟁이 치열합니다.

바이오마커는 개인 맞춤형 의료의 핵심으로 더 나은 환자 치료와 더 효과적인 치료를 가능하게 합니다. 따라서 정밀의료로의 전환은 바이오마커 검사 서비스에 대한 수요를 뒷받침하는 중요한 요인 중 하나이며, 이로 인해 시장 성장이 증가할 것입니다. 예를 들어, 2022년 1월 화이자(Pfizer Inc.)와 빔 테라퓨틱스(Beam Therapeutics Inc.)는 희귀 유전성 질환에 대한 정밀 의료를 개발하기 위해 4년간의 독점적인 공동 연구 계약을 발표했습니다.

COVID-19 팬데믹은 시장에 중간 정도의 영향을 미쳤으며, COVID-19 팬데믹 초기에는 바이오마커 검사 서비스를 포함한 임상시험을 포함한 여행 제한으로 인해 임상시험에 큰 영향을 미쳤습니다. 그러나 COVID-19 진단용 바이오마커의 빠른 개발로 시장은 손실을 회복했습니다. 바이러스 RNA를 표적으로 하는 PCR 분석이나 바이러스 단백질을 검출하는 항원 검사 등 바이오마커 기반 검사는 바이러스를 식별하고 추적하는 데 매우 중요합니다.

바이오마커 임상 단계 아웃소싱 서비스 시장 보고서 하이라이트

  • 바이오마커 유형별로는 대체 엔드포인트 분야가 2022년 56.0%로 가장 큰 점유율을 차지했습니다. 정밀 의약품에 대한 수요 증가와 바이오마커 분석을 활용한 임상시험의 증가가 이 분야의 성장을 견인하고 있습니다.
  • 치료 분야별로는 암 분야가 2022년 34.6%로 가장 큰 점유율을 차지했습니다. 이 분야가 높은 점유율을 보이는 주요 이유는 암의 조기 발견 및 진단을 위한 암 바이오마커에 대한 수요가 증가하고 있기 때문입니다.
  • 바이오테크놀러지 기업은 새로운 바이오마커 검사 서비스 개발에 투자하는 바이오제약 기업이 증가함에 따라 분석 기간 동안 20.8%의 CAGR을 기록할 것으로 예상됩니다.
  • 아시아태평양은 예측 기간 동안 21.4%의 가장 높은 CAGR을 기록할 것으로 예상됩니다. 높은 성장은 주로 중국, 인도 등 신흥 경제국에 제조 활동을 아웃소싱하는 유럽 및 미국 제약 기업의 증가에 기인합니다.

목차

제1장 조사 방법과 범위

제2장 주요 요약

제3장 바이오마커 임상 단계 아웃소싱 서비스 시장 변수, 동향 및 범위

  • 시장 계통 전망
    • 상부 시장 전망
    • 관련/부수 시장 전망
  • 시장 역학
    • 시장 성장 촉진요인 분석
    • 시장 성장 억제요인 분석
  • 바이오마커 임상 단계 아웃소싱 서비스 시장 분석 툴
    • 업계 분석 - Porter's Five Forces 분석
    • PESTEL 분석
    • COVID-19 감염증의 영향 분석

제4장 바이오마커 임상 단계 아웃소싱 서비스 시장 : 바이오마커 종류 추정·동향 분석

  • 바이오마커 임상 단계 아웃소싱 서비스 시장, 바이오마커 유형별 : 부문 대시보드
  • 바이오마커 임상 단계 아웃소싱 서비스 시장, 바이오마커 유형별 : 변동 분석

제5장 바이오마커 임상 단계 아웃소싱 서비스 시장 : 치료 분야 추정·동향 분석

  • 바이오마커 임상 단계 아웃소싱 서비스 시장, 치료 분야별 : 부문 대시보드
  • 바이오마커 임상 단계 아웃소싱 서비스 시장, 치료 분야별 : 변동 분석

제6장 바이오마커 임상 단계 아웃소싱 서비스 시장 : 최종 용도 추정·동향 분석

  • 바이오마커 임상 단계 아웃소싱 서비스 시장, 최종 용도별 : 부문 대시보드
  • 바이오마커 임상 단계 아웃소싱 서비스 시장, 최종 용도별 : 변동 분석

제7장 바이오마커 임상 단계 아웃소싱 서비스 시장 : 지역 추정·동향 분석

  • 지역 시장 점유율 분석, 2022년 및 2030년
  • 지역 시장 대시보드
  • 세계의 지역 시장 현황
  • 북미
    • 시장 추정과 예측, 2018-2030년
    • 미국
    • 캐나다
  • 유럽
    • 영국
    • 독일
    • 프랑스
    • 이탈리아
    • 스페인
    • 덴마크
    • 스웨덴
    • 노르웨이
  • 아시아태평양
    • 일본
    • 인도
    • 중국
    • 한국
    • 호주
    • 태국
  • 라틴아메리카
    • 브라질
    • 멕시코
    • 아르헨티나
  • 중동 및 아프리카
    • 남아프리카공화국
    • 사우디아라비아
    • 아랍에미리트
    • 쿠웨이트

제8장 경쟁 상황

  • 시장 진출 기업 분류
    • 이노베이터
    • 시장 리더
    • 신흥 기업
    • 기업의 시장 점유율 분석, 2022년
  • 기업 개요
    • Laboratory Corporation of America Holdings
    • Parexel International Corporation
    • ICON plc
    • Charles River Laboratories
    • Proteome Sciences
    • Fujirebio
    • WuXi AppTec
    • NorthEast BioAnalytical Laboratories LLC.
    • Celerion
    • GenScript ProBio
ksm 23.11.16

Biomarker Clinical Phase Outsourcing Services Market Growth & Trends:

The global biomarker clinical phase outsourcing services market size is expected to reach USD 27.17 billion by 2030, registering a CAGR of 20.6%, according to a new report by Grand View Research, Inc.. Increasing diagnostic applications of biomarkers, rapid advancements in OMICS technologies, a rise in research and development (R&D) funding from the government, and the shift toward precision medicine are a few of the factors driving the growth of the market.

The market is fragmented, with several key players having similar technological and processing capabilities. These companies offer various services related to biomarker testing, including assay development, sample analysis, data interpretation, and clinical trial support. This industry is characterized by intense competition driven by factors such as quality assurance, technological advancements, regulatory compliance, and the ability to offer high-value and diverse services.

Biomarkers are at the core of personalized medicine, enabling better patient care and more effective treatments. Hence, the shift towards precision medicine is another significant factor supporting demand for biomarker testing services, thereby augmenting market growth. For instance, in January 2022, Pfizer Inc. and Beam Therapeutics Inc. announced an exclusive four-year research collaboration agreement to develop precision medicines for rare genetic diseases.

The COVID-19 pandemic moderately impacted the market. The initial phase of the COVID-19 pandemic has significantly affected clinical trials due to travel restrictions, including trials involving biomarker testing services. However, the market recovered from the losses due to the rapid development of biomarkers for COVID-19 diagnosis. Biomarker-based tests, such as PCR assays targeting viral RNA and antigen tests detecting viral proteins, have been crucial for identifying and tracking the virus.

Biomarker Clinical Phase Outsourcing Services Market Report Highlights:

  • Based on biomarker type, the surrogate endpoints segment accounted for the largest share of 56.0% in 2022. The segment's growth is driven by the growing demand for precision medicines and the rise in the number of clinical trials involving the use of biomarker analysis
  • Based on therapeutic area, the oncology segment accounted for the largest share of 34.6% in 2022. High segment shares are majorly due to the increasing demand for cancer biomarkers for early detection and diagnosis of the condition
  • Based on end-use, the biotechnology companies are anticipated to witness the highest CAGR of 20.8% across the analysis timeframe due to the increasing number of biopharmaceutical companies investing in developing novel biomarker testing services
  • Asia Pacific is anticipated to witness the highest CAGR of 21.4% during the forecast time frame. High growth is primarily due to increasing number of Western pharmaceutical companies outsourcing their manufacturing activities to developing economies such as China and India

Table of Contents

Chapter 1. Research Methodology and Scope

  • 1.1. Market Segmentation & Scope
    • 1.1.1. Segment Definitions
    • 1.1.2. Biomarker Type
    • 1.1.3. Therapeutic Area
    • 1.1.4. End-use
  • 1.2. Regional Scope
  • 1.3. Estimates And Forecast Timeline
  • 1.4. Objectives
    • 1.4.1. Objective-1
    • 1.4.2. Objective-2
    • 1.4.3. Objective-3
  • 1.5. Research Methodology
  • 1.6. Information Procurement
    • 1.6.1. Purchased Database
    • 1.6.2. GVR's Internal Database
    • 1.6.3. Secondary Sources
    • 1.6.4. Primary Research
  • 1.7. Information Or Data Analysis
    • 1.7.1. Data Analysis Models
  • 1.8. Market Formulation & Validation
  • 1.9. Model Details
    • 1.9.1. Commodity Flow Analysis
    • 1.9.2. Parent Market Analysis
  • 1.10. List Of Secondary Sources
  • 1.11. List Of Abbreviations

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Outlook
  • 2.3. Competitive Insights

Chapter 3. Biomarker Clinical Phase Outsourcing Services Market Variables, Trends & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent Market Outlook
    • 3.1.2. Related/Ancillary Market Outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market Driver Analysis
      • 3.2.1.1. Increasing diagnostic applications of biomarkers
      • 3.2.1.2. Rise in R&D funding from the government
      • 3.2.1.3. Rapid advancements in technologies such as genomics, proteomics, and imaging
      • 3.2.1.4. The shift toward precision medicine
    • 3.2.2. Market Restraint Analysis
      • 3.2.2.1. High capital investment
      • 3.2.2.2. Challenges related to quality control
  • 3.3. Biomarker Clinical Phase Outsourcing Services Market Analysis Tools
    • 3.3.1. Industry Analysis - Porter's
      • 3.3.1.1. Supplier Power
      • 3.3.1.2. Buyer Power
      • 3.3.1.3. Substitution Threat
      • 3.3.1.4. Threat Of New Entrant
      • 3.3.1.5. Competitive Rivalry
    • 3.3.2. PESTEL Analysis
    • 3.3.3. COVID-19 Impact Analysis

Chapter 4. Biomarker Clinical Phase Outsourcing Services Market: Biomarker Type Estimates & Trend Analysis

  • 4.1. Biomarker Clinical Phase Outsourcing Services Market, By Biomarker Type: Segment Dashboard
  • 4.2. Biomarker Clinical Phase Outsourcing Services Market, By Biomarker Type: Movement Analysis
  • 4.3. Biomarker Clinical Phase Outsourcing Services Market Estimates & Forecasts, By Biomarker Type, 2018 - 2030
    • 4.3.1. Predictive Biomarkers
      • 4.3.1.1. Predictive Biomarkers Clinical Phase Outsourcing Services Market, 2018 to 2030 (USD Million)
    • 4.3.2. Prognostic Biomarkers
      • 4.3.2.1. Prognostic Biomarkers Clinical Phase Outsourcing Services Market, 2018 to 2030 (USD Million)
    • 4.3.3. Safety Biomarkers
      • 4.3.3.1. Safety Biomarkers Clinical Phase Outsourcing Services Market, 2018 to 2030 (USD Million)
    • 4.3.4. Surrogate Endpoints
      • 4.3.4.1. Surrogate Endpoints Clinical Phase Outsourcing Services Market, 2018 to 2030 (USD Million)

Chapter 5. Biomarker Clinical Phase Outsourcing Services Market: Therapeutic Area Estimates & Trend Analysis

  • 5.1. Biomarker Clinical Phase Outsourcing Services Market, By Therapeutic Area: Segment Dashboard
  • 5.2. Biomarker Clinical Phase Outsourcing Services Market, By Therapeutic Area: Movement Analysis
  • 5.3. Biomarker Clinical Phase Outsourcing Services Market Estimates & Forecasts, By Therapeutic Area, 2018 - 2030
    • 5.3.1. Oncology
      • 5.3.1.1. Oncology Biomarker Clinical Phase Outsourcing Services Market, 2018 to 2030 (USD Million)
    • 5.3.2. Neurology
      • 5.3.2.1. Neurology Biomarker Clinical Phase Outsourcing Services Market, 2018 to 2030 (USD Million)
    • 5.3.3. Cardiology
      • 5.3.3.1. Cardiology Biomarker Clinical Phase Outsourcing Services Market, 2018 to 2030 (USD Million)
    • 5.3.4. Autoimmune Diseases
      • 5.3.4.1. Autoimmune Diseases Biomarker Clinical Phase Outsourcing Services Market, 2018 to 2030 (USD Million)
    • 5.3.5. Others
      • 5.3.5.1. Others Biomarker Clinical Phase Outsourcing Services Market, 2018 to 2030 (USD Million)

Chapter 6. Biomarker Clinical Phase Outsourcing Services Market: End-use Estimates & Trend Analysis

  • 6.1. Biomarker Clinical Phase Outsourcing Services Market, By End-use: Segment Dashboard
  • 6.2. Biomarker Clinical Phase Outsourcing Services Market, By End-use: Movement Analysis
  • 6.3. Biomarker Clinical Phase Outsourcing Services Market Estimates & Forecasts, By End-use, 2018 - 2030
    • 6.3.1. Pharmaceutical Companies
      • 6.3.1.1. Pharmaceutical Companies Biomarker Clinical Phase Outsourcing Services Market 2018 to 2030 (USD Million)
    • 6.3.2. Biotechnology Companies
      • 6.3.2.1. Biotechnology Companies Biomarker Clinical Phase Outsourcing Services Market 2018 to 2030 (USD Million)
    • 6.3.3. Others
      • 6.3.3.1. Others Biomarker Clinical Phase Outsourcing Services Market 2018 to 2030 (USD Million)

Chapter 7. Biomarker Clinical Phase Outsourcing Services Market: Regional Estimates & Trend Analysis

  • 7.1. Regional Market Share Analysis, 2022 & 2030
  • 7.2. Regional Market Dashboard
  • 7.3. Global Regional Market Snapshot
  • 7.4. North America
    • 7.4.1. Market Estimates and Forecast, 2018 - 2030 (Revenue, USD Million)
    • 7.4.2. U.S.
      • 7.4.2.1. Key Country Dynamics
      • 7.4.2.2. Competitive Scenario
      • 7.4.2.3. Regulatory Framework
      • 7.4.2.4. U.S. Market Estimates and Forecasts, 2018 - 2030
    • 7.4.3. Canada
      • 7.4.3.1. Key Country Dynamics
      • 7.4.3.2. Competitive Scenario
      • 7.4.3.3. Regulatory Framework
      • 7.4.3.4. Canada Market Estimates and Forecasts, 2018 - 2030
  • 7.5. Europe
    • 7.5.1. UK
      • 7.5.1.1. Key Country Dynamics
      • 7.5.1.2. Competitive Scenario
      • 7.5.1.3. Regulatory Framework
      • 7.5.1.4. UK Market Estimates and Forecasts, 2018 - 2030
    • 7.5.2. Germany
      • 7.5.2.1. Key Country Dynamics
      • 7.5.2.2. Competitive Scenario
      • 7.5.2.3. Regulatory Framework
      • 7.5.2.4. Germany Market Estimates and Forecasts, 2018 - 2030
    • 7.5.3. France
      • 7.5.3.1. Key Country Dynamics
      • 7.5.3.2. Competitive Scenario
      • 7.5.3.3. Regulatory Framework
      • 7.5.3.4. France Market Estimates and Forecasts, 2018 - 2030
    • 7.5.4. Italy
      • 7.5.4.1. Key Country Dynamics
      • 7.5.4.2. Competitive Scenario
      • 7.5.4.3. Regulatory Framework
      • 7.5.4.4. Italy Market Estimates and Forecasts, 2018 - 2030
    • 7.5.5. Spain
      • 7.5.5.1. Key Country Dynamics
      • 7.5.5.2. Competitive Scenario
      • 7.5.5.3. Regulatory Framework
      • 7.5.5.4. Spain Market Estimates and Forecasts, 2018 - 2030
    • 7.5.6. Denmark
      • 7.5.6.1. Key Country Dynamics
      • 7.5.6.2. Competitive Scenario
      • 7.5.6.3. Regulatory Framework
      • 7.5.6.4. Denmark Market Estimates and Forecasts, 2018 - 2030
    • 7.5.7. Sweden
      • 7.5.7.1. Key Country Dynamics
      • 7.5.7.2. Competitive Scenario
      • 7.5.7.3. Regulatory Framework
      • 7.5.7.4. Sweden Market Estimates and Forecasts, 2018 - 2030
    • 7.5.8. Norway
      • 7.5.8.1. Key Country Dynamics
      • 7.5.8.2. Competitive Scenario
      • 7.5.8.3. Regulatory Framework
      • 7.5.8.4. Norway Market Estimates and Forecasts, 2018 - 2030
  • 7.6. Asia Pacific
    • 7.6.1. Japan
      • 7.6.1.1. Key Country Dynamics
      • 7.6.1.2. Competitive Scenario
      • 7.6.1.3. Regulatory Framework
      • 7.6.1.4. Japan Market Estimates and Forecasts, 2018 - 2030
    • 7.6.2. India
      • 7.6.2.1. Key Country Dynamics
      • 7.6.2.2. Competitive Scenario
      • 7.6.2.3. Regulatory Framework
      • 7.6.2.4. India Market Estimates and Forecasts, 2018 - 2030
    • 7.6.3. China
      • 7.6.3.1. Key Country Dynamics
      • 7.6.3.2. Competitive Scenario
      • 7.6.3.3. Regulatory Framework
      • 7.6.3.4. China Market Estimates and Forecasts, 2018 - 2030
    • 7.6.4. South Korea
      • 7.6.4.1. Key Country Dynamics
      • 7.6.4.2. Competitive Scenario
      • 7.6.4.3. Regulatory Framework
      • 7.6.4.4. South Korea Market Estimates and Forecasts, 2018 - 2030
    • 7.6.5. Australia
      • 7.6.5.1. Key Country Dynamics
      • 7.6.5.2. Competitive Scenario
      • 7.6.5.3. Regulatory Framework
      • 7.6.5.4. Australia Market Estimates and Forecasts, 2018 - 2030
    • 7.6.6. Thailand
      • 7.6.6.1. Key Country Dynamics
      • 7.6.6.2. Competitive Scenario
      • 7.6.6.3. Regulatory Framework
      • 7.6.6.4. Thailand Market Estimates and Forecasts, 2018 - 2030
  • 7.7. Latin America
    • 7.7.1. Brazil
      • 7.7.1.1. Key Country Dynamics
      • 7.7.1.2. Competitive Scenario
      • 7.7.1.3. Regulatory Framework
      • 7.7.1.4. Brazil Market Estimates and Forecasts, 2018 - 2030
    • 7.7.2. Mexico
      • 7.7.2.1. Key Country Dynamics
      • 7.7.2.2. Competitive Scenario
      • 7.7.2.3. Regulatory Framework
      • 7.7.2.4. Mexico Market Estimates and Forecasts, 2018 - 2030
    • 7.7.3. Argentina
      • 7.7.3.1. Key Country Dynamics
      • 7.7.3.2. Competitive Scenario
      • 7.7.3.3. Regulatory Framework
      • 7.7.3.4. Argentina Market Estimates and Forecasts, 2018 - 2030
  • 7.8. MEA
    • 7.8.1. South Africa
      • 7.8.1.1. Key Country Dynamics
      • 7.8.1.2. Competitive Scenario
      • 7.8.1.3. Regulatory Framework
      • 7.8.1.4. South Africa Market Estimates and Forecasts, 2018 - 2030
    • 7.8.2. Saudi Arabia
      • 7.8.2.1. Key Country Dynamics
      • 7.8.2.2. Competitive Scenario
      • 7.8.2.3. Regulatory Framework
      • 7.8.2.4. Saudi Arabia Market Estimates and Forecasts, 2018 - 2030
    • 7.8.3. UAE
      • 7.8.3.1. Key Country Dynamics
      • 7.8.3.2. Competitive Scenario
      • 7.8.3.3. Regulatory Framework
      • 7.8.3.4. UAE Market Estimates and Forecasts, 2018 - 2030
    • 7.8.4. Kuwait
      • 7.8.4.1. Key Country Dynamics
      • 7.8.4.2. Competitive Scenario
      • 7.8.4.3. Regulatory Framework
      • 7.8.4.4. Kuwait Market Estimates and Forecasts, 2018 - 2030

Chapter 8. Competitive Landscape

  • 8.1. Market Participant Categorization
    • 8.1.1. Innovators
    • 8.1.2. Market Leaders
    • 8.1.3. Emerging Players
    • 8.1.4. Company Market Share Analysis, 2022
  • 8.2. Company Profiles
    • 8.2.1. Laboratory Corporation of America Holdings
      • 8.2.1.1. Company Overview
      • 8.2.1.2. Financial Performance
      • 8.2.1.3. Service Benchmarking
      • 8.2.1.4. Strategic Initiatives
    • 8.2.2. Parexel International Corporation
      • 8.2.2.1. Company Overview
      • 8.2.2.2. Financial Performance
      • 8.2.2.3. Service Benchmarking
      • 8.2.2.4. Strategic Initiatives
    • 8.2.3. ICON plc
      • 8.2.3.1. Company Overview
      • 8.2.3.2. Financial Performance
      • 8.2.3.3. Service Benchmarking
      • 8.2.3.4. Strategic Initiatives
    • 8.2.4. Charles River Laboratories
      • 8.2.4.1. Company Overview
      • 8.2.4.2. Financial Performance
      • 8.2.4.3. Service Benchmarking
      • 8.2.4.4. Strategic Initiatives
    • 8.2.5. Proteome Sciences
      • 8.2.5.1. Company Overview
      • 8.2.5.2. Financial Performance
      • 8.2.5.3. Service Benchmarking
      • 8.2.5.4. Strategic Initiatives
    • 8.2.6. Fujirebio
      • 8.2.6.1. Company Overview
      • 8.2.6.2. Financial Performance
      • 8.2.6.3. Service Benchmarking
      • 8.2.6.4. Strategic Initiatives
    • 8.2.7. WuXi AppTec
      • 8.2.7.1. Company Overview
      • 8.2.7.2. Financial Performance
      • 8.2.7.3. Service Benchmarking
      • 8.2.7.4. Strategic Initiatives
    • 8.2.8. NorthEast BioAnalytical Laboratories LLC.
      • 8.2.8.1. Company Overview
      • 8.2.8.2. Financial Performance
      • 8.2.8.3. Service Benchmarking
      • 8.2.8.4. Strategic Initiatives
    • 8.2.9. Celerion
      • 8.2.9.1. Company Overview
      • 8.2.9.2. Financial Performance
      • 8.2.9.3. Service Benchmarking
      • 8.2.9.4. Strategic Initiatives
    • 8.2.10. GenScript ProBio
      • 8.2.10.1. Company Overview
      • 8.2.10.2. Financial Performance
      • 8.2.10.3. Service Benchmarking
      • 8.2.10.4. Strategic Initiatives
비교리스트
0 건의 상품을 선택 중
상품 비교하기
전체삭제